Klaviyo Insider Sold Shares Worth $3,437,114, According to a Recent SEC Filing-April 2024-www.financetom.com

Klaviyo Insider Sold Shares Worth $3,437,114, According to a Recent SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Klaviyo Insider Sold Shares Worth $3,437,114, According to a Recent SEC Filing

Apr 17, 2026 1:03 AM

03:39 AM EDT, 04/17/2026 (MT Newswires) -- Andrew Bialecki, 10% Owner, Director, Co-Chief Executive Officer, on April 14, 2026, sold 200,000 shares in Klaviyo ( KVYO ) for $3,437,114.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1835830/000147083126000375/xslF345X05/wk-form4_1776384250.xml

Previous page： Update: Affiliated Managers Group Shares Fall After Q3 Results Fall Behind Estimates Next page： --Street Color: Uber Plans to Lower Minimum Wage of New York City Drivers, Bloomberg Reports

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Update: Affiliated Managers Group Shares Fall After Q3 Results Fall Behind Estimates

Nov 4, 2024

01:35 PM EST, 11/04/2024 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph) Affiliated Managers Group ( AMG ) shares fell 9% after the firm's Q3 earnings failed to meet estimates. The company reported Q3 economic earnings of $4.82 per share, up from $4.08 a year earlier. Analysts polled by Capital IQ expected $4.84. Total...

--Street Color: Uber Plans to Lower Minimum Wage of New York City Drivers, Bloomberg Reports

Nov 4, 2024

01:40 PM EST, 11/04/2024 (MT Newswires) -- Price: 73.67, Change: +0.42, Percent Change: +0.57 ...

Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug

Nov 4, 2024

On Monday, Ascendis Pharma A/S ( ASND ) granted Novo Nordisk A/S ( NVO ) an exclusive worldwide license. The pact will focus on the TransCon technology platform to develop, manufacture, and commercialize Novo Nordisk ( NVO ) proprietary products for metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license for cardiovascular diseases. Also Read: Ascendis...

Update: Chemours Shares Jump After Q3 Results Come Ahead of Estimates

Nov 4, 2024

01:32 PM EST, 11/04/2024 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph) Chemours ( CC ) shares jumped nearly 16% in recent Monday trading after the company's Q3 results came ahead of estimates. The company reported Q3 adjusted earnings of $0.40 per diluted share, down from $0.43 a year earlier. Analysts surveyed by Capital...